NCT02935517 - Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 3, 2017

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2026

Conditions

Achromatopsia

Interventions

BIOLOGICAL

AGTC-402

AGTC-402 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGA3 gene.

Trial Locations (6)

VitreoRetinal Associates, Gainesville

Bascom Palmer Eye Institute, Miami

Cincinnati Eye Institute, Cincinnati

Hadassah-Hebrew University Medical Center, Jerusalem

Casey Eye Institute, Oregon Health and Sciences University, Portland

Massachusetts Eye and Ear Infirmary, Boston